Kallyope Inc. has identified new gastrin-releasing peptide receptor (GRPR) agonists potentially useful for the treatment of gastrointestinal disorders and obesity.

Kallyope Inc. has outlined plans to initiate phase I studies this year with K-554, a non-incretin peptide candidate offering a new mechanism of action in obesity.

Kallyope has divulged compounds acting as tachykinin NK3 receptor antagonists reported to be useful for the treatment of migraine.

The prospects of an oral obesity candidate used as a monotherapy or combination therapy is in question after Kallyope Inc. posted disappointing phase II data on a government website, indicating that its lead candidate, K-757, failed to meet all endpoints.

Kallyope Inc. has identified new tachykinin NK3 receptor antagonists reported to be useful for the treatment of migraine.

Kallyope Inc. has synthesized compounds acting as tachykinin NK3 receptor antagonists.

Novo Nordisk A/S has exercised an option to license a ligand identified by Kallyope Inc. for further development, including as a potential new approach for the treatment of obesity.

Kallyope Inc. patent details new AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of type 2 diabetes, allergy, cancer, depression, nutrition disorders, obesity, psoriasis and ulcerative colitis, among others.

Recent Kallyope Inc. patents report AMP-activated protein kinase (AMPK) activators potentially useful for the treatment of allergy, cancer, depression, diabetes type 2, nutrition disorders, obesity, psoriasis, inflammatory bowel disease, metabolic syndrome, nonalcoholic steatohepatitis, Alzheimer’s and Parkinson’s disease, among others.